Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerwin Huls

Showing results (131-140 of 162) with videos related to

Pageof 17
Sort By:
Haematologica|November 11, 2017
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Chloé Reiniers, Timothy Bagguley, et al.
European Journal of Heart Failure|October 12, 2022
Clonal haematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkersCanxia Shi, Joseph Pierre Aboumsallem, Navin Suthahar, et al.
Annals of Hematology|October 4, 2024
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcomeGerwin Huls, Dana A Chitu, Lidwine Tick, et al.
Bone Marrow Transplantation|April 30, 2020
Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profileLotte E van der Wagen, Alberto Miranda-Bedate, Anke Janssen, et al.
American Journal of Hematology|July 1, 2025
MRD Assessment in Patients With Acute Myeloid Leukemia Aged ≥ 60 Years Treated With a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 StudyAdriano Venditti, Michal Kicinski, Ernesta Audisio, et al.
Haematologica|April 21, 2018
GFI1 is required for <i>RUNX1/ETO</i> positive acute myeloid leukemiaAnna E Marneth, Lacramioara Botezatu, Judith M Hönes, et al.
Annals of Hematology|November 25, 2015
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study GroupMichael Lübbert, Stefan Suciu, Anne Hagemeijer, et al.
Leukemia|February 27, 2025
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agentsTom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, et al.
Blood Cancer Journal|November 8, 2022
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagyKeli Lima, Diego Antonio Pereira-Martins, Lívia Bassani Lins de Miranda, et al.
Haematologica|May 28, 2026
The oncogenic ΔNp73 isoform contributes to aggressiveness in acute promyelocytic leukemiaCésar Alexander Ortiz Rojas, Diego Antonio Pereira-Martins, Carolina Hassibe Thomé, et al.
Pageof 17

Showing results (131-140 of 162) with videos related to

Sort By:
Pageof 17
Haematologica|November 11, 2017
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Chloé Reiniers, Timothy Bagguley, et al.
European Journal of Heart Failure|October 12, 2022
Clonal haematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkersCanxia Shi, Joseph Pierre Aboumsallem, Navin Suthahar, et al.
Annals of Hematology|October 4, 2024
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcomeGerwin Huls, Dana A Chitu, Lidwine Tick, et al.
Bone Marrow Transplantation|April 30, 2020
Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profileLotte E van der Wagen, Alberto Miranda-Bedate, Anke Janssen, et al.
American Journal of Hematology|July 1, 2025
MRD Assessment in Patients With Acute Myeloid Leukemia Aged ≥ 60 Years Treated With a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 StudyAdriano Venditti, Michal Kicinski, Ernesta Audisio, et al.
Haematologica|April 21, 2018
GFI1 is required for <i>RUNX1/ETO</i> positive acute myeloid leukemiaAnna E Marneth, Lacramioara Botezatu, Judith M Hönes, et al.
Annals of Hematology|November 25, 2015
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study GroupMichael Lübbert, Stefan Suciu, Anne Hagemeijer, et al.
Leukemia|February 27, 2025
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agentsTom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, et al.
Blood Cancer Journal|November 8, 2022
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagyKeli Lima, Diego Antonio Pereira-Martins, Lívia Bassani Lins de Miranda, et al.
Haematologica|May 28, 2026
The oncogenic ΔNp73 isoform contributes to aggressiveness in acute promyelocytic leukemiaCésar Alexander Ortiz Rojas, Diego Antonio Pereira-Martins, Carolina Hassibe Thomé, et al.
Pageof 17